Targovax with full year report
Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.
Author Archive for: oslocancer
Entries by oslocancer
Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway
Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).
Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
Survival rate of 68% from first patient cohort vs published historical rate of 30-53% suggests signal of clinical efficacy for the drug candidate. Full data set from first patient cohort to be submitted for presentation at ASCO annual meeting in June.
Lytix Biopharma granted 15.9 MNOK from The Norwegian Research Council
Oslo Cancer Cluster member Lytix Biopharma has been awarded a NOK 15.9 million grant from The Norwegian Research Council.
